Related Experiment Video
Updated: May 11, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
Published on: August 18, 2020
Aripiprazole for treating cannabis-induced psychotic symptoms in ultrahigh-risk individuals
Benjamin Rolland1, Pierre Alexis Geoffroy, Renaud Jardri
1PRES Nord de France and Department of Psychiatry, Paediatric Psychiatry and Addiction Medicine, CHU Lille, Lille, France. benjamin.rolland@chru-lille.fr
Abstract:
Cannabis-induced psychotic symptoms (CIPSs) have both similarities and differences with positive symptoms of schizophrenia, and it remains unclear whether CIPSs result from dopaminergic mechanisms and can be treated with antipsychotics. We report the case of a 22-year-old male patient with ultrahigh risk criteria for psychosis, who reported cannabis addiction and recurrent CIPSs. Aripiprazole 10 mg/d could totally and durably suppress CIPSs in the patient, but had no effect on the smoking level. Treating CIPSs in ultrahigh risk individuals who cannot stop or refuse stopping cannabis might fit a harm-reduction strategy by preventing transition into psychosis.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
